Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219744 | 0.89 | PTPN1 (0.56) | PTPN1MAPTKMT2ANPC1KDM4E | |
| SCHEMBL9218345 | 0.89 | CA1 (0.56) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL3417705 | 0.88 | CA1 (0.61) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL29591307 | 0.88 | CA1 (0.61) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL9216643 | 0.86 | PTPN1 (0.56) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL11901558 | 0.86 | MAPT (0.57) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL9217844 | 0.85 | L3MBTL1 (0.49) | PTPN1MAPTKMT2ANPC1KDM4E | |
| SCHEMBL974921 | 0.83 | PTPN1 (0.54) | PTPN1CA1CA2MAPTKMT2A | |
| SCHEMBL9217459 | 0.83 | PTPN1 (0.50) | PTPN1CA1CA2MAPTKDM4E | |
| SCHEMBL27947376 | 0.82 | MAPT (0.54) | PTPN1CA1CA2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215823-A | FXR (FXR) regulator and preparation method, pharmaceutical composition and application thereof | 青岛睿吉医疗技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
| EP-0512570-B1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-10-11 | — | — | EP | disclosed |
| CN-1067886-A | New urea derivatives, their preparation method and pharmaceutical composition thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-01-13 | — | — | CN | disclosed |
| EP-0512570-A1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4124603-A | ANTIMICROBIAL | RIKER LABORATORIES, INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-4067993-A | Antimicrobial 2-nitro-3-phenylbenzofurancarboxylic acids | RIKER LABORATORIES, INC. (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | PTPN1 4237/4885CA1 508/4885CA2 306/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | PTPN1 4237/4885CA1 508/4885CA2 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.